• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Nanoform announces construction of new GMP manufacturing facility

Finnish nanotechnology company Nanoform has announced construction of a new 600m2 GMP manufacturing facility at Viikki Life Science Park in Helsinki. The plant, which is expected to be operational sometime in 2019, will result in a six-fold increase the company’s capacity for nanonization of API for clinical trial use and will add the capability to handle potent APIs. Funding for the expansion was partially provided by a €7 million private placement.

According to the company, its supercritical CO2 technology is capable of producing particles from 10 nm to 2 µm and can control the polymorphism of the particles. The company cites an increased ability for these particles to cross the blood brain barrier when delivered intranasally as a potential benefit of the process.

Nanoform Chief Commercial Officer Christian Jones commented, “We are very excited to announce the constructionof our new GMP-compliant facility, a key milestone in our growth strategy. We believe we are the only company globally that can produce excipient-free nanoparticles below 200nm directly from solution and at scale, whilst controlling their physico-chemical attributes. This offers significant advantage for our customers development molecules, enabling solutions to problematic compounds, transforming existing formulations and adding lifecycle protection to current pipeline drugs.”

Read the Nanoform press release.

Share

published on December 13, 2018

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews